Weikang Bio-Technology to Present at PHARMCHINA'S 64th National Drug Fair Conference

HARBIN, China, Nov. 24, 2010 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced it will present at PHARMCHINA'S 64th National Medicine Trade Conference to be held in Nanchang from December 9 -11, 2010.

"The National Drug Fair is the most important conference for our industry.  It attracts over 100,000 visitors, making it an excellent opportunity for us to introduce our newly launched therapeutics to a large number of retailers, hospitals officials, pharmacists, distributors and sales agents as well as strengthen our reputation as a manufacturer of high-quality therapeutics," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group.  "Additionally, the conference will provide us with the opportunity to expand our knowledge on the latest cutting-edge research and drug development technology."

PHARMCHINA's National Drug Fair is the largest conference on therapeutics and related technology and services in China.  Over 1,900 domestic and foreign enterprises will participate as well as key officials from the National Commerce Department, Ministry of Health, State Food and Drug Association and China Association of Pharmaceutical Commerce.  At the conference, officials and industry leaders will exchange ideas regarding global health topics as well as ways to improve China's drug industry, including industry reform, reduction in counterfeiting and encouragement of innovation.  

About Weikang Bio-Technology Group Co., Inc.

Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang Pharmaceutical Co., Ltd.  For more information, please visit

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.  These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investors Relation contacts:

John Marco, Partner, Elite IR

Tel:   +1-310-819-2948


Leslie J. Richardson, Partner, Elite IR

Tel:    +852-3183-0283


Source: Weikang Bio-Technology Group Co., Inc.
Related Stocks: